ST. JOSEPH, Mo. (May 28, 2009) – Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces Drs. Keith Bretey, Erin Johnson, Jeff Okones and Brian Payne, all professional service veterinarians for the company’s swine division, completed the Executive Veterinary Program (EVP) for Swine Health and Production program at the University of Illinois.
The program, offered through the University of Illinois College of Veterinary Medicine, is a two-year continuing education program designed to enhance the business, communication and planning skills of busy animal health professionals. The program consists of ten two-day interactive educational modules focused on swine health management. Module topics cover essential aspects of swine production and health maintenance to enhance the management, consultation and problem-solving skills of veterinarians.
“Our veterinarians are devoted to providing the best clinical service and information to our customers. Keith, Erin, Jeff and Brian’s participation in this program demonstrates our continuing dedication at Boehringer Ingelheim to improving the swine health practices in the industry,” says Tyler Holck, associate director of swine professional services for BIVI.
More than 35 veterinarians from 12 states completed the program this April. The award-winning program uses nationally-recognized experts from academia and industry to deliver relevant knowledge. The program has more than 200 graduates since its inception in 1991.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit: www.bi-vetmedica.com.